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A Plasma Inhibitor of the Renin-Antirenin Reaction 
and the In Vitro Generation of Angiotensin I 
C. P. Lucas. W. K. Waldhausl, E. L. Cohen, F. G. Berlinger, 
W. J. McDonald, and R. S. Sider 
In the course of studies designed to develop However, it could be separated from renin 
a radioimmunoassay system for the de- substrate by ion-exchange chromatog- 
tection of renin, we have identified in raphy. When fractions containing this 
human plasma a potent inhibitor that in- activity were tested in an in vitro system 
terferes with the renin-antirenin reaction. containing renin and renin substrate, they 
Utilizing gel filtration, this renin-antirenin were found to inhibit the generation of an- 
inhibitory activity was found to have the giotensin I. 
same molecular size as renin substrate. 
vv HEN PLASMA is incubated at 37°C the reaction that takes place be- tween the enzyme renin and its substrate, in the presence of certain added 
inhibitors to angiotensinanses and converting enzyme, results in the generation of 
angiotensin I (AI). The rate of this reaction can be determined by either bioassay 
or radioimmunoassay of AI, and this function is referred to as plasma renin 
activity (PRA). It is generally recognized that variousfactors besides renin, such 
as inhibitors,lp3 activators, or the concentration of renin substrate4-7 influence 
the PRA. Thus the correlations between renin concentration (by indirect 
methods) and PRA in plasma of normal people and in plasma of women on oral 
contraceptives do not run exactly parallel.7 
The theoretical advantages in having a method for the direct measurement of 
renin in blood are thus obvious. The recent availability of a highly purified 
preparation of human renin* and potent antisera to it encouraged us to explore 
the feasibility of developing a radioimmunoassay for renin. In the course of our 
investigation we labeled human renin with iodine-131 without detectable 
“damage.” By employing a double-antibody technique to separate free 1311-renin 
from that bound to antibody, we found that we could detect both purified renin in 
buffer and endogenous renin in human plasma. The most striking observation 
made was the detection of a plasma inhibitor to the renin-antirenin reaction. This 
inhibitor later proved to have the same molecular size as renin substrate, but 
could be separated from the latter by ion-exchange chromatography. When 
tested in an in vitro system, in the presence of exogenous renin and renin 
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substrate, this renin-antirenin inhibiting fraction was found to decrease the 
generation of angiotensin I. 
MATERIALS AND METHODS 
Sephadex G-200 was purchased from Pharmacia Fine Chemicals, Uppsala, Sweden, and DEAE 
cellulose from Sigma Chemical Co., St. Louis, MO. Bovine serum albumin (Fraction V) was obtained 
from Armour Pharmaceutical Co., Chicago, and Nai3’I from Union Carbide Corp., New York. 
Pooled plasma used for the isolation of renin substrate was obtained from Michigan State Labora- 
tories, Lansing, Mich. (The combined plasma of 600 normotensive donors was used to form the pool.) 
Preparation of an tire& and radioiodinated renin. Purified human renin’ was used both for the 
production of antirenin and for labeling with radioactive iodine. Antirenin was produced in New Zea- 
land rabbits injected subcutaneously at biweekly intervals with 0.5 mg of purified human renin mixed 
with complete Freund’s adjuvant. Antibody titers were estimated by determining the dilutions of anti- 
serum needed to inhibit the renin activity of normal human plasma. Purified human renin (1.5 pg) with 
a potency of 5 to 13 Goldblatt units per milligram was labeled with I mCi of Na13’I by either the 
method of Hunter and Greenwood0 or the method of McFarlane.“’ Radioiodinated renin, with a 
specific activity of 100-200 mCi/mg, was purified by polyacrylamide disc-gel electrophoresis, using 
10.5% acrylamide (pH 8.9). 
Collection and handling of blood specimens. Blood from normal subjects and from hypertensive 
patients was collected in ammonium EDTA (final concentration 3 mM) and was chilled immediately 
in ice. Plasma was separated by centrifugation and stored at -20°C until the time of assay. 
Renin radioimmunoassay. For this radioimmunoassay, all reactions were run at 4’C. Dilutions of 
reagents were made with borate buffer (8.25 g boric acid, 2.7 g NaOH, 1.86 g Na,EDTA, 0. I g mer- 
thiolate in 1 liter of water, adjusted to pH 8.0 with HCI) containing I % bovine serum albumin. The in- 
cubation mixture contained 0. I ml of radioiodinated renin (approximately 10,000 c.p.m.), 0. I ml of a 
1:10,000 dilution of antirenin, 0.05 to 0.2 ml of plasma to be assayed or 0.1 ml of purified renin stan- 
dard (75 to 5,OlXl pg per tube), and 0.3 to 0.45 ml of borate buffer, to bring the initial reaction volume 
to 0.7 ml. Free ‘s’I-renin was separated from antibody-bound ia1I-renin after 48-96 hr incubation, by 
double antibody precipitation of soluble renin-antirenin complex. I1 Radioactivity was measured in a 
Packard Autogamma counter. Values for renin determined by radioimmunoassay are expressed as 
nanograms per milliliter. 
Renin activity assay. All plasmas assayed in the renin radioimmunoassay were also assayed for 
renin activity by the rat bioassay, using a modiication of the Boucher method.‘l Results are expressed 
as nanogram equivalents of angiotensin II generated per 100 ml of blood during a 3-hr incubation at 
37°C. 
Tests for damage to radioiodinated renin. Equal volumes of radioiodinated renin (100,000 c.p.m./ 
0.1 ml) and human plasma were incubated at 4°C for 24, 48, 96, 120, and 144 hr. This mixture was 
then run in a polyacrylamidedisc-gel electrophoresis system (10.5% acrylamide, pH 8.9). 
Complement fixation. Inhibition by human serum of the renin-antirenin reaction was studied by 
complement fixation.la 
Isolation form human plasma of both an inhibitor to the renin-antirenin reaction and an inhibitor 
to the in vitro generation of angiotensin I. Pooled human plasma was fractionated at 4°C by (1) 
Sephadex G-200 chromatography, employing a 2.5- x RIO-cm column, eluted with a 0.075-M phos- 
phate buffer, pH 7.5; and (2) by DEAE cellulose chromatography, employing a 5- x 40-cm column, 
eluted with an ascending salt gradient (from zero to 0.25-M NaCI) in 0.01-M acetate buffer, pH 5.5. 
Fractions were collected and assayed for substrate concentration and renin-antirenin inhibitory 
activity. Certain fractions were then pooled, concentrated, and tested for (1) inhibition to the 
generation of angiotensin I by renin and (2) angiotensinase activity. 
1. Assay for plasma inhibitor to the renin-antirenin reaction: It was found quite early in the de- 
velopment of the radioimmunoassay for renin that low-renin-activity plasma (or anephric plasma) 
could inhibit the binding of “iI-renin to antirenin (see Fig. 1). Therefore, a particular low-renin- 
activity plasma was chosen as a laboratory standard against which inhibitory activity to the renin- 
antirenin reaction could be measured. Dilutions of this plasma were used in place of renin standards in 
the renin radioimmunoassay described above. This standard curve was used to estimate inhibitory 
activity in fractions obtained from chromatography. This inhibitory activity was expressed as 
microliter equivalents of this standard plasma. 
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Fig. 1. Standard curve (with circles) of radioim- 
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2. Assay for inhibitor to the enzymatic action of renin: Fractions obtained from DEAE cellulose 
and Sephadex G-200 chromatography were combined (pools A, B, C, D, C,, and C, as shown in Figs. 
4 and 6) and concentrated (Diaflo ultrafiltration apparatus), and then dialyzed against 0.1-M acetate 
buffer (pH 5.6). Assay for inhibitory activity (enzymatic) was made by adding 50 ~1 of the con- 
centrated pool to 50 pl of plasma (pH 5.6) serving as renin substrate, 10 ~1 of 0.3-M disodium ethy- 
lenediaminetetracetate, 2 PI of diisopropylfluorophosphate (DFP) solution (I:3 dilution of DFP with 
isopropanol), and IO pl of human renin (see Fig. 5 and Table 4 for other details). In control assays 50 
~1 of 0.1-M acetate buffer (pH 5.6) containing 1% bovine serum albumin was substituted for pooled 
fractions. These mixtures were incubated for 30 min at 37” C, and the angiotension I generated was 
measured by radioimmunoassay.” Pooled fractions found to diminish the amount of angiotensin I 
were tested for angiotensinase activity by substituting 10 11 of angiotensin I for the 10 ~1 of renin in the 
above mixtures prior to incubation (final concentration approximately 10 ng AI/ml, see Table 3). 
3. Assay for substrate concentration: Eluates from DEAE cellulose and Sephadex G-200 
chromatography were assayed for substrate concentration by incubating 50 ccl of eluate with 5 aI of 
0.03-M disodium EDTA, 2 ~1 of DFP solution, and 6 pl of an angiotensinase-free preparation of 
human renin (equivalent to lo-* Goldblatt units) for I hr at 37°C. Substrate activity was estimated by 
measuring the amount of generated angiotensin I employing a radioimmunoassay.15 
RESULTS 
Renin Radioimmunoassay: Correlation with Bioassay 
A standard curve for the renin radioimmunoassay is shown in Fig. 1 (mean 
curve of 20 assays). The results comparing immunoreactive renin (IRR) with 
PRA, as performed on a total of 448 human plasma specimens in 20 separate 
assays, are shown in Table 1. The correlation between IRR and PRA is 
significant for three groups of plasmas in which the average PRA of the group is 
high (assays 25,34, and 117). In assays where the average PRA is lower, correla- 
tions are always positive but often not statistically significant. 
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16.3 +0.878 S 
12.3 +0.657 s 
4.1 +0.090 NS 
3.85 +0.512 S 
4.65 +0.020 NS 
4.35 +0.471 S 
5.74 +0.216 NS 
5.53 +0.203 NS 
5.44 +0.267 NS 
2.01 +0.337 NS 
4.25 +0.636 S 
3.66 +0.190 NS 
2.55 +0.188 NS 
2.3 +0.412 NS 
12.5 +0.530 S 
8.44 +0.130 NS 
0.9 +0.354 NS 
0.9 1 +0.316 NS 
1.87 +0.168 NS 
3.67 +0.588 S 
N = number of samples in assay. 
r = coefficient of correlation. 
NS indicates that the correlation was not statistically significant at the 5% level of confidence, 
while S indicates statistical significance at the 5% level or beyond. 
Inhibition by Plasma to the Renin-Antirenin Reaction 
Not due to renin content of plasma. Figure 1 shows inhibition to binding of 
1311-renin to antirenin, induced (a) by added renin standard and (b) by plasma that 
contains very low renin activity (undetectable by bioassay). As little as 50 ~1 of 
this plasma significantly decreased binding of 1311-renin to antirenin. With in- 
creasing amounts of plasma, the curve becomes similar but not identical to the 
standard curve of the radioimmunoassay. Since the amount of renin estimated in 
the low-renin-activity plasma is probably too low to account for this observed 
degree of inhibition, and since a similar effect was produced by plasma obtained 
from anephric individuals, it seems probable that this inhibitory activity is not 
due to renal renin. 
Failure to find signiJicant incubation damage to radioiodinated renin. NO de- 
tectable change was observed in the polyacrylamide electrophoretic pattern of 
1311-renin that had been preincubated with human plasma at 4°C for periods up to 
6 days (see Fig. 2). Furthermore, 1311-renin that was eluted from the poly- 
acrylamide did not exhibit any decline in binding due to this incubation, upon the 
addition of excess antirenin (70% bind vs. 59% for control, using double-antibody 
technique). 
Inhibition of complement fixation. Highly purified renin and various titers of 
antirenin were incubated overnight with and without human serum, and these 
reactions were tested for complement fixation (Table 2). Renin and antirenin in- 
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Fig. 2. ‘all-ranin profile following frac- 
tionation by polyocrylamide disc-gel dec- 
trophoresis. ‘“I-rennin had previously bwn 
incubated with human plasma or buffsr (as 
a control) fur 6 days at 4°C. Gels were cut in 
l-mm slica, and the radiiactctivity of each 
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Table 2. Inhibition of Complement Fixation’ by Normal Human Serum 
Antigen Antibody:Dilution 1 :2 1 :4 1 :8 1 :16 1 :32 1 :64 1 :128 1.258 1 :512 1 .1024 1 :2048 1.4096 
Renul Antirenin wth 
0.8 #g/ml buffer 444443 3 3 3 3 2 0 
Renin Antirenin with 
0.8 rwml serum diluted 1 .5 432 0 0 0 0 0 0 0 0 0 
Renin Antirenin with 
O.Erg/ml serum diluted 1 :50 4 4 3 0 0 0 0 0 0 0 0 0 
‘Complement fixation graded 0 to 4. Presence of serum associated with decrease in fixation of complement 












Fig. 3. Profile of renin substrate activity and renin-antirennin inhibitory activity in fractions ob.. 
tained from Sephadex G-200 column chromatography of pooled human plasma. 
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cubated with buffer alone resulted in fixation of complement. On the other hand, 
significant inhibition of complement fixation occurred when this same reaction 
was studied in the presence of human serum in dilutions of 15 and 1:50. 
Isolation of Inhibitor 
When pooled plasma from normotensive donors was fractionated by Sephadex 
G-200 column chromatography, renin-antirenin inhibitory activity eluted as a 
distinct peak (Fig. 3). As determined by its elution volume, the molecular weight 
of this peak was about 75,000 (compared with renin, MW 40,000). Furthermore, 
the peak of the renin-antirenin inhibitory activity correlated very closely with the 
peak of substrate activity. However, when this same pooled plasma was frac- 
tionated by DEAE cellulose chromatography (Fig. 4), renin-antirenin inhibitory 
activity eluted over a wider range. The largest peak preceded the substrate frac- 
tions, while a minor band correlated with the appearance of the substrate peak. 
Beyond that point renin-antirenin inhibitory activity was undetectable, while 
substrate activity continued to elute. 
The fractions obtained from DEAE cellulose chromatography were combined 
into four pools (see Fig. 4), concentrated 60-fold, and tested for inhibition to the 
FRACTION NUMBER 
“Pools” +A- B-C-D- 
Fig. 4. Profile of renin substrate activity and renin-antirenin inhibitory activity in fractions obtained 
from DEAE cdluloso column chromatography of pooled human plasma. 
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Fig. 5. Meesurement of 
inhibitory ectivity to the 
enzymatic action of renin in 
pools obteined from DEAE 
cellulose column chroma- 
togrnphy (see Fig. 4, pools 
A-D). Experiments were 
carried out es described in 
Methods, section 2. Low- 
renin-ectfvfty plasma was 
used as e substrate source 
(S). Human renin ~8s 
diluted serially with buffer, 
and 10 ~1 of the verious di- 
lutions were added to each 
sample. giving the range of 
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RENIN CONCENTRATION in 10.4 G.U. /ml 
Table 3. Enzyme Inhibitory and Angiotensinase Activities of Pooled Fractions 
Enzyme lnhibitoryActn+’ Angiotensinase Activity’ 
Al 
Generation % % 
” Flatat lnhibmon P ” ng Al/ml Degradation p 
Control 10 4.41 f 0.13 - - 10 7.3 f 0.63 - - 
Pool B (DEAE) 9 3.53 + 0.10 20.0 0.0002 10 4.7 f 0.09 36 0.001 
Pool C (DEAEI 10 2.55 f 0.09 42.2 0.000001 5 5.6 f 0.38 24 0.048 
Control 9 6.25 f 0.08 - - 11 10.5*0.51 - - 
Pool C, (G-200) 9 6.07 f 0.14 2.8 0.29 5 11.7zko.95 - 0.25 
Pool C, (G-200) 9 5.17 f 0.17 17.3 0.000 1 12 11.1 f 0.77 - 0.54 
n = number of replicate samples run. 
p = statistical significance level. 
‘Assays were run as described in Methods. section 2. Low-renin-activity plasma was used as a sub- 
strate source. In the assay for enzyme inhibitory activity, renin concentrations were the same as those 
used in the experiments shown in Fig. 5. 
t Rate measured as nanograms Al per hour per lOa Goldblatt units of renin {mean f SEM) 
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enzymatic action of renin. Only pools B and C appeared to inhibit the generation 
of angiotensin I (Fig. 5 and Table 3). The apparent inhibitory activity of pool B 
was found to be 20’%, while that of pool C was 42%. Studies were performed to 
determine whether this apparent decrease in AI generation might be due to an- 
giotensinase activity. As shown in Table 3, pools B and C degraded 36% and 24% 
of added AI, respectively. Thus pool C had a greater ratio of apparent inhibi- 
tory:angiotensinase activity than B. 
Therefore pool C was further purified by Sephadex G-200 column chromatog- 
raphy. Renin-antirenin inhibitory activity was found in the second of two protein 
peaks (Fig. 6). The fractions from each peak were pooled and concentrated 15 
fold (pools C, and C,). These pools were dialyzed against 0.1-M acetate buffer 
(pH 5.5) and tested for angiotensinase activity to AI and for inhibitory activity to 
the enzymatic action of renin as before. Results of these studies are also shown in 
Table 3. Neither pool exhibited any angiotensinase activity. However, pool C, 
was found to contain significant inhibitory activity to the enzymatic action of 
renin. This pool was further tested for enzymatic inhibition, using plasmas of 
both normal subjects (normal-renin-activity group) and patients with low renin 
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Fig. 6. Profile of renin-antirenin inhibiiory activity following Sephadex G-200 column 
chromatography of fraction C. 
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Table 4. Enzymatic Inhibitory Activity of Pool C2 Tested Against Individual 
Plasmas of Normal People and Patients with Low-Renin Hypertension 
(LRH) and Primary Aldosteronism 11 OAl 
Subject 
Condition’ 
and PRA nt 
% Inhibttory 
Actwtyt 
284 Normal (7.5) 5 3.3 
301 Normal (12.5) 5 16.0 
305 Normal (6.0) 5 - 6.3 
313 Normal (2.2) 5 23.0 
352 Normal (16.4) 5 18.5 
382 Normal (1.9) 5 5.8 
398 Normal (7.0) 5 9.2 













1 ‘A (0.29) 
1 ‘A (0.371 
1 ‘A (0.69) 







5 27 0 
20.8 f 1.67 
-- 
0.022 
*Condition of subject (i.e.. normal. LRH. 1 ‘A) and PRA of the subject’s plasma, which was used as a 
substrate source in that experiment. PRAs (shown in parentheses) were determined by radioimmunoas- 
say for Al and are expressed as ng/ml/hr.14 
t Each control and experimental assay was run in quintuplicate. 
tMean percentage inhibitory activcty as compared to controls. Assays were run as described In 
Methods, section 2: 10 I of human renin (1.8 x 10m2 G.U./ml) was added to bring the final renin 
concentration to 1.5x 10-3G.U./ml. 
source (Table 4). In vitro inhibitory activity was observed against all but one 
normal plasma, the mean inhibition being 9.9% from control. When low-renin- 
activity plasmas were used as a substrate source, mean inhibitory activity of pool 
C, was 20.8% from control. The difference between these means (9.9 vs. 20.8) was 
significant at the 0.05 level. 
DISCUSSION 
Plasma renin activity is a measure of the in vitro reaction between plasma renin 
and its substrate at 37°C. This reaction rate is affected by factors in plasma 
besides renin, probably renin inhibitors and/or renin substrate.1-7 These facts 
raise the question of the capability of PRA assays to measure plasma renin con- 
centration (PRC). It was for this reason that we attempted to develop a radioim- 
munoassay for renin. There are indirect methods for measuring renin, one of 
which utilizes heterologous substrate added in great excess to the plasma sample 
before generation of AI. Alternatively, the in vitro assay for PRA can be 
modified by the addition of purified human renin as an internal standard.15 In this 
way it is possible to reliably measure PRC. Employing this latter method we have 
found the correlation between PRA and PRC of 22 normotensive subjects to be 
highly significant, r = +0.728 (unpublished data). In the present report we have 
employed a renin radioimmunoassay method to measure PRC, which we refer to 
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as immunoreactive renin (IRR). The correlation coefficients (r) for each of the 20 
assays in which PRA and IRR were measured ranged from +0.020 to +0.878 
(Table 1). Though always positive, only 7 of 20 had correlations significant at the 
5% level, and thus most correlations fall short of the theoretical norm referred to 
above. In the 7 assays where r was significant, the average PRAs tended to be 
high (e.g., assays 25, 34, and 117). Although these results, taken as a whole, indi- 
cate that the 1311-renin-antirenin system we have developed is capable of de- 
tecting renin in human plasma, they also indicate that certain discrepancies exist 
when comparing renin concentration measured by the radioimmunoassay (IRR) 
to that measured by the indirect method described above (PRC). 
In this regard, the results illustrated in Fig. 1 may explain this discrepancy. 
Here we have evidence that another factor besides renin affects the radioim- 
munoassay system, since low-renin-activity plasma (and plasma of anephric indi- 
viduals) is shown to inhibit binding of 1311-renin to antirenin. The presence of this 
other factor is supported by the results shown in Table 2, where, employing non- 
radioactive renin and using the technique of complement fixation, we observed in- 
terference by serum with the renin-antirenin reaction. This phenomenon does not 
appear to be caused by incubation damage to renin (Fig. 2). Rather, it appears to 
be caused by a reaction of the radioimmunoassay reagents with a specific protein 
or proteins, as the results described in Figs. 3 and 4 suggest. The tracing in Fig. 3 
indicates that the renin-antirenin inhibitor of plasma has the same molecular size 
as renin substrate. This correlation has been repeatedly demonstrated in indi- 
vidual plasma samples fractionated by Sephadex G-200 column chromatog- 
raphy. Were it not for the study employing DEAE cellulose chromatography of 
the same plasma, one might conclude that the renin-antirenin inhibitor is renin 
substrate. From the study illustrated in Fig. 4, however, it is clear that the renin- 
antirenin inhibitor and renin substrate overlap but are not identical. We see, for 
example, that the major inhibitory fraction elutes slightly ahead of the substrate 
fractions. A minor inhibitory peak then corresponds with the appearance of the 
substrate fractions, and while fractions containing substrate activity continue to 
elute, inhibitory activity has ceased. Thus there exists the real possibility that the 
renin-antirenin inhibitor may be made up of certain renin-substrate fractions as 
well as other fractions with the same molecular size as renin substrate, but not 
containing substrate activity. 
Our suspicion that the renin-antirenin inhibitor might also possess inhibitory 
activity against the enzymatic action of renin prompted us to investigate this 
possibility. Pool C obtained from DEAE cellulose column chromatography (Fig. 
4) and pool C, obtained from Sephadex G-200 column chromatography of C 
(Fig. 6) were thus found to possess both renin-antirenin inhibitory activity and in- 
hibitory activity against the enzymatic action of renin (Tables 3 and 4). When 
pool C, and renin, the latter added in excess, were added to low-PRA plasma 
serving as a substrate source, a 17.3% inhibition (from control) of AI generation 
resulted, p < 0.0001 (Table 3). The experiments illustrated in Table 4 were con- 
ducted to study the inhibitory effect of pool C, when several other plasmas were 
used as a substrate source. We chose the plasma of 7 normal people and the 
plasma of 7 people with low PRA for this experiment. As the results in Table 4 
show, pool C, inhibitor produced significantly more inhibition when low-PRA 
plasma was used as a substrate source than when normal-PRA plasma was used. 
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A problem, of course, is how to interpret these results. Skeggs has proposed 
that hog-renin substrate is an a*-globulin to which is attached a 14 amino acid 
peptide (tetradecapeptide). Renin reacts with the tetradecapeptide moiety, split- 
ting off the 10 amino acid angiotensin I. I6 From our unpublished studies we know 
the molecular weight of human renin substrate to be about 75,000. Since an- 
giotensin I has a molecular weight of 1300, we can conclude that the reaction be- 
tween renin and its substrate is as follows: 
renin substrate product 1 product 2 
(a,-globulin) a (angiotensin I) + (a,-globulin) 
MW 75,000 MW 1300 MW 73,700 
We can also conclude that in the relative absence of renin, little of product 2 is 
being formed. Thus a plasma may have varying ratios of renin substrate to 
product 2. On the basis of this formulation, and from the results seen in Fig. 3, we 
can speculate that the renin-antirenin inhibitor could be either renin substrate 
(MW 75,000) and/or product 2 (MW 73,700). since both of these have essentiall:y 
the same size and should migrate together on Sephadex G-200. On the other 
hand, renin substrate and product 2 (which has no substrate activity) could easily 
possess a difference in charge accounting for the results seen with anion-exchange 
chromatography (Fig. 4), where renin-antirenin inhibitor and substrate are sep- 
arate but overlap. It would also make sense that renin substrate or product 2 
could interact stereochemically with renin and thus could interfere with the 
renin-antirenin reaction. In addition, product 2 could interfere with renin’s ca- 
pacity to react with its own substrate and may qualify as inhibitor of enzymatic 
activity. These concepts need to be tested. Nevertheless, they are consistent with 
the various observations that we and others have made. For example, anephric 
plasma has been shown to produce less inhibition to renin added in vivo or in 
vitro.” This presumably could be due in part to the relative deficiency of product 
2. In our studies anephric plasma has been found to contain renin-antirenin in- 
hibitory activity. This could be explained by the presence of renin substrate in the 
absence of product 2. In our studies we have shown that inhibitor (pool C,) has 
more activity when added to low-PRA than when added to normal-PRA plasma. 
One possible interpretation of these data is that there is a greater quantity of 
endogenous inhibitor in normal-PRA plasmas and that addition of (pool C,) in- 
hibitor to them might have less effect, if the inhibitory response is not linear. Of 
particular relevance to this thesis is our recent observation that reactivity of 
plasma (defined as the generation rate of angiotensin I on addition of renin, and 
used here as an index of inhibitory capacity of plasma) was inversely related to 
the plasma renin concentration in a study of 88 plasma samples. Is Further studies 
of course are needed, especially those dealing with the in vitro generation and sub- 
sequent purification of product 2 from renin substrate. 
The presence of an inhibitor to renin in plasma has previously been reported, l7 
and the kidney has been assumed to be a possible source.1g-22 This inhibitor has 
been identified as a phospholipid. Recently a great deal of interest has been 
created by the observation that different plasmas generate AI unequally 
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following the addition of exogenous renin, an observation first made by Boucher 
et al. in 1964, as well as by Pickens et al. in 1965.‘e2 It is still not possible, 
however, based on our own data or that of others, to state with any degree of 
certainty that a physiologic renin inhibitor does exist, although certain lines of 
investigation are suggested. However, our studies clearly describe an interaction 
between renin and a specific serum factor or factors that makes a radioim- 
munoassay for renin difficult. It is probably fair to say that much more work will 
be necessary before success in this area can be realized. 
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